查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
全球膿毒症診斷市場：市場趨勢及至2031年預測
市場調查報告書
商品編碼
1868995

全球膿毒症診斷市場：市場趨勢及至2031年預測

Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031
出版日期: | 出版商: Kalorama Information | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

敗血症仍然是現代醫學面臨的最迫切、成本最高的挑戰之一。敗血症的特徵是機體對感染產生危及生命的免疫反應，每年影響全球約2,700萬人，造成500萬人死亡。光是在美國，每年就有約200萬例膿毒症病例和27萬例死亡。早期發現對於提高存活率至關重要，但由於每位患者的症狀複雜多樣，早期發現仍然極具挑戰性。敗血症是美國醫院治療費用最高的疾病，因此，對準確、快速且易於取得的診斷工具的需求從未如此迫切。

Kalorama Information發布的 "全球膿毒症診斷市場－市場趨勢及至2031年預測" 報告對全球膿毒症診斷市場進行了全面評估，涵蓋體外診斷（IVD）、分子診斷及相關檢測方法。本報告提供截至 2031 年的全球銷售數據和預測，涵蓋所有主要地區以及美國、中國、印度和日本等關鍵市場。

全面的研究方法和可靠的數據

市場規模估算以目前美元為單位，代表臨床實驗室、醫院和診所最終用戶在敗血症診斷產品和耗材上的總支出。本分析不包括用於執行這些測試的診斷設備和系統的成本，以確保報告數據準確反映產品使用趨勢。所有貨幣換算均使用購買力平價指數，以確保各地區的一致性。

本研究基於廣泛的一手和二手研究，包括對行業專家和製造商的訪談、政府和行業數據以及市場領導者的最新公開披露資訊。此外，還參考了部分 Kalorama 出版物和行業報告，以驗證研究結果並識別新興趨勢。

本報告的重要性

隨著全球醫療保健系統將早期檢測、成本控制和患者預後放在首位，本報告提供了評估膿毒症診斷市場格局所需的關鍵市場情報。它為以下方面提供了數據驅動的基礎：

  • 主要地區的市場規模估算與預測
  • 診斷開發商之間的競爭基準分析
  • 投資、合作與產品擴張的策略規劃

隨著敗血症帶來的臨床和經濟負擔不斷推動創新， "全球膿毒症診斷產品市場－市場趨勢和預測（至2031年）" 報告幫助決策者獲得重要洞察，並駕馭不斷發展的全球醫療診斷產業。

目錄

第一章：摘要整理

第二章：引言

  • 膿毒症概述
    • 診斷工具
    • 應用範圍
  • 專業指南與定義
    • 全身性發炎反應症候群 (SIRS) 標準和敗血症 - 1
    • 敗血症 - 2
    • 敗血症 - 3
    • 戰勝敗血症運動
    • 序貫器官衰竭評估 (SOFA) 和定量序列器官衰竭評估 (qSOFA) 評分
  • 市場考量

第三章 生物標記

  • 乳酸、C 反應蛋白 (CRP)、降鈣素原 (PCT) 和其他生物標記
  • 概述
  • 膿毒症中使用的生物標記
    • 降鈣素原 (PCT)
  • C反應蛋白 (CRP)
    • 乳酸
    • 細胞因子
    • RNA、mRNA 和 microRNA (miRNA)
    • 腎上腺髓質素原 (ProADM)
    • D-二聚體
  • 多標記檢測方法
    • 主要公司和平台

第四章 分子檢測與質譜分析

  • 病原體鑑定和表徵
  • 多重分子偵測
    • 膿毒症中使用的多重分子檢測
    • 質譜分析
    • 微生物鑑定與藥敏試驗產品
    • 個人化醫療

第五章：市面上及研發中主要的敗血症相關產品

  • 診斷產品及新興技術
  • 產品開發問題
  • 人工智慧和機器學習在敗血症診斷的應用

第六章：敗血症診斷市場預測

  • 敗血症診斷市場概況
  • 敗血症生物標記市場
  • 敗血症分子檢測與質譜市場
  • 主要參與者的競爭格局

第7章 企業簡介

  • 市場動態
  • ABBOTT
  • ABIONIC
  • ACCELERATE DIAGNOSTICS
  • BAYESIAN HEALTH
  • BECTON, DICKINSON AND COMPANY (BD)
  • BIOMERIEUX
  • BRUKER CORPORATION
  • CELLECTRIC BIOSCIENCES
  • CUBE DX
  • CYTOVALE
  • DANAHER CORPORATION
  • DIASORIN
  • FLUILUX
  • GENMARK DIAGNOSTICS/HOLOGIC
  • GRADIENTECH
  • HELIXBIND
  • IMMUNEXPRESS
  • KARIUS
  • INFLAMMATIX
  • MEMED
  • MOLZYM GMBH
  • MOMENTUM BIOSCIENCES
  • NOVUS DIAGNOSTICS
  • OCEAN DX
  • PRENOSIS
  • Q-LINEA
  • QIAGEN
  • QUIDELORTHO
  • RADIOMETER
  • ROCHE
  • SEEGENE
  • SIEMENS HEALTHINEERS
  • T2 BIOSYSTEMS
  • TEMPUS
  • THERMO FISHER SCIENTIFIC
簡介目錄
Product Code: 25-077KA

Sepsis remains one of the most urgent and costly challenges in modern healthcare. Characterized by a life-threatening immune response to infection, sepsis affects an estimated 27 million people and causes 5 million deaths worldwide each year, including approximately 2 million cases and 270,000 deaths in the United States alone. Early detection is critical to survival, yet remains difficult due to the condition's complex and variable presentation across patients. As the most expensive condition treated in U.S. hospitals, the need for accurate, rapid, and accessible diagnostic tools has never been greater.

Kalorama Information's "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" delivers a comprehensive assessment of the worldwide market for sepsis diagnostic products, including in vitro diagnostics (IVD), molecular diagnostics, and related testing approaches. The report provides global sales data and projections through 2031 for all major world regions and for key individual markets-the United States, China, India, and Japan.

Comprehensive Methodology and Reliable Data

Market estimates are presented in current U.S. dollars, representing total end-user spending on sepsis diagnostic products and consumables by clinical laboratories, hospitals, and physicians' offices. The analysis excludes the cost of diagnostic instruments and systems implementing these tests, ensuring that reported figures specifically reflect product utilization trends. All currency conversions were made using purchasing power indices for consistency across regions.

The study is built upon extensive primary and secondary research, including interviews with industry experts and manufacturers, government and trade data, and the latest public filings from market leaders. Selected Kalorama publications and industry reports were also leveraged to validate findings and identify evolving trends.

Why This Report Matters

With healthcare systems worldwide prioritizing early detection, cost containment, and patient outcomes, this report provides the critical market intelligence needed to evaluate the sepsis diagnostics landscape. It offers a data-driven foundation for:

  • Market sizing and forecasting across key geographies
  • Competitive benchmarking among diagnostic developers
  • Strategic planning for investment, partnerships, and product expansion

As the clinical and economic burden of sepsis continues to drive innovation, "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" equips decision-makers with the insights necessary to navigate a growing and essential area of global healthcare diagnostics.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • HIGHLIGHTS
    • Diagnostic Approaches and Technologies
    • Market Size and Competition
    • 3 Key Takeaways from This Report
  • SCOPE AND METHODOLOGY
    • Methodology
    • Sources of Information
  • ABOUT KALORAMA INFORMATION

CHAPTER 2: INTRODUCTION

  • SEPSIS OVERVIEW
    • Diagnostic Tools
    • Scope of Use
  • PROFESSIONAL GUIDELINES AND DEFINITIONS
    • SIRS Criteria and Sepsis-1
    • Sepsis-2
    • Sepsis-3
    • Surviving Sepsis Campaign
    • SOFA and qSOFA Scores
  • MARKET CONSIDERATIONS
    • Table 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]

CHAPTER 3: BIOMARKERS

  • Table 3-1: Top Biomarkers Used in Sepsis, 2025
  • Lactate, C-Reactive Protein (CRP), Procalcitonin (PCT) and Other Biomarkers
  • Overview
    • Figure 3-1: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Test Volume, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
    • Figure 3-2: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Sales Revenues, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
  • BIOMARKERS USED FOR SEPSIS
    • Procalcitonin (PCT)
  • C-Reactive Protein (CRP)
    • Lactate
    • Cytokines
    • RNA, mRNA, microRNA (miRNA)
    • Proadrenomedullin (ProADM)
    • D-Dimer
  • MULTI-MARKER APPROACHES
    • Key Companies and Platforms

CHAPTER 4: MOLECULAR ASSAYS AND MASS SPECTROMETRY

  • PATHOGEN IDENTIFICATION AND CHARACTERIZATION
  • MULTIPLEX MOLECULAR ASSAYS
    • Multiplex Molecular Assays Used for Sepsis
      • Table 4-1: Multiplex Molecular Assays Used for Sepsis, 2025
    • Mass Spectrometry
    • Products for Microbe Identification and AST
      • Table 4-2: Selected Mass Spectrometry Products Used for Microbial ID and AST, 2025
      • Table 4-3: Systems and Products for Bacterial Culture, Staining, Incubation, 2025
    • Personalized Medicine

CHAPTER 5: MAJOR SEPSIS-RELATED PRODUCTS ON THE MARKET AND UNDER DEVELOPMENT

  • DIAGNOSTIC PRODUCTS AND EMERGING TECHNOLOGIES
    • Table 5-1: Sepsis Diagnostic Products on the Market, 2025
  • PRODUCT DEVELOPMENT ISSUES
    • The Challenge in Modern Sepsis Management
    • The Financial Incentive vs. The Adoption Hurdle
    • The Chasm Between Innovation and Practice
    • The Verification and Liability Problem
    • Current Status
  • ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SEPSIS DIAGNOSIS
    • Applications of AI/ML in Sepsis Diagnosis
    • Currently Available AI/ML Products for Sepsis Diagnosis
    • AI/ML Products Under Development and Emerging Trends
    • Future AI/ML Systems Are Integrating Diverse Data Types Beyond Standard EHRs
    • Challenges to Adoption and Performance
    • Future Trends

CHAPTER 6: SEPSIS DIAGNOSTICS MARKET ESTIMATES

  • Total Sepsis Diagnostics Market
    • Table 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 6-2: Total Global Market Share for Sepsis Diagnostics, 2025 vs. 2031 (%) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Table 6-2: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-3: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-4: Global Market for Sepsis Diagnostics, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Sepsis Biomarker Market
    • Table 6-3: Total Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
    • Figure 6-5: Global Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
    • Table 6-4: Global Market for Sepsis Biomarkers, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-6: Global Market for Sepsis Biomarkers, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Market for Sepsis Molecular Assays and Mass Spectrometry
    • Table 6-5: Total Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
    • Figure 6-7: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
    • Table 6-6: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-8: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-9: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Competitive Positions of the Major Players
    • Table 6-7: Leading Providers of Sepsis Diagnostic Products, by 2025 Sales ($ million) and Share (%)
    • Figure 6-10: Leading Providers of Sepsis Diagnostic Products, by Sales, 2025 ($ million)
    • Figure 6-11: Leading Providers of Sepsis Diagnostic Products, by Share, 2025 (%)
  • Market Leader Discussion

CHAPTER 7: COMPANY PROFILES

  • MARKET DYNAMICS
    • Inactive Companies and Products
    • Companies No Longer Focused on Sepsis Diagnostics
    • Companies Currently Active in the Sepsis Diagnostics Market
  • ABBOTT
    • Immunoassay Biomarkers
    • Molecular Diagnostics
    • Point-of-Care (POC) Solutions
    • Microbiology and Culture Systems
  • ABIONIC
    • abioSCOPE-R Platform and PSP Test
    • Pancreatic Stone Protein (PSP) as a Sepsis Biomarker
    • Testing Process and Interpretation
    • Clinical Benefits of PSP Detection
    • Limitations and Future Outlook
  • ACCELERATE DIAGNOSTICS
    • Core Technologies for Sepsis Management
    • Accelerate Pheno-R System
    • Accelerate Arc(TM) System
    • Future Innovation: Accelerate WAVE(TM) System
    • Strategic Impact on Sepsis Care
  • BAYESIAN HEALTH
    • Sepsis Detection with TREWS
    • Workflow Integration and Explainability
    • Clinical Validation and Impact
    • Challenges and Future Outlook
    • Broader Applications
  • BECTON, DICKINSON AND COMPANY (BD)
    • Blood Culture
    • Mass Spectrometry
  • BIOMERIEUX
    • Traditional Microbiology
    • Biomarkers for Sepsis
    • Blood Culture Systems
    • Immunoassays
    • Mass Spectrometry
  • BRUKER CORPORATION
    • Mass Spectrometry
    • Molecular Diagnostics
    • Strategic Acquisitions
  • CELLECTRIC BIOSCIENCES
    • Benefits for Sepsis Diagnosis and Management
    • Limitations and Challenges
  • CUBE DX
    • Core Technology and Applications
    • Technology Platform: hybcell
    • Benefits for Sepsis Management
    • Limitations and Considerations
  • CYTOVALE
    • IntelliSep: Technology Overview
    • Risk Stratification Bands
    • Clinical Impact and Benefits
    • Limitations and Considerations
  • DANAHER CORPORATION
    • Cepheid
    • Integrated Strategy
  • DIASORIN
    • Molecular Diagnostics Expansion
  • FLUILUX
    • Technology Overview
    • Clinical Impact on Sepsis Management
    • Limitations and Considerations
  • GENMARK DIAGNOSTICS/HOLOGIC
  • GRADIENTECH
  • HELIXBIND
  • IMMUNEXPRESS
    • SeptiCyte RAPID
    • Next Generation Products
  • KARIUS
  • INFLAMMATIX
    • TriVerity(TM)
    • Research
  • MEMED
    • MeMed BV
    • MeMed Severity
  • MOLZYM GMBH
    • MolYsis Technology
    • Diagnostic Products
    • Clinical Impact and Considerations
  • MOMENTUM BIOSCIENCES
  • NOVUS DIAGNOSTICS
  • OCEAN DX
  • PRENOSIS
  • Q-LINEA
  • QIAGEN
    • QIAstat-Dx
    • Sample Preparation Technologies
    • Digital PCR (dPCR)
    • Antimicrobial Resistance (AMR) Research Solutions
  • QUIDELORTHO
    • VITROS Sepsis Assay Menu
    • Point-of-Care (POC) Testing Solutions
    • Benefits in Sepsis Management
    • Limitations and Considerations
  • RADIOMETER
    • Blood Gas Analysis
    • Immunoassays
    • Integrated Solutions and Clinical Intelligence
  • ROCHE
    • Biomarkers
    • Molecular Assays
    • Point-of-Care and Critical Care Solutions
    • Digital and Integrated Solutions
  • SEEGENE
    • Magicplex(TM) Sepsis Real-time Test
    • Underlying Technology
    • Clinical Benefits
    • Limitations
  • SIEMENS HEALTHINEERS
  • T2 BIOSYSTEMS
    • The T2Dx-R Instrument
    • T2Candida-R Panel
    • T2Bacteria-R Panel
    • T2Resistance-R Panel
    • The T2MR Technology
  • TEMPUS
  • THERMO FISHER SCIENTIFIC
    • Immunoassays
    • Microbiology
    • Blood Culture